Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia

BACKGROUND: Chronic myeloid leukaemia (CML) is a haematological cancer featured by the presence of BCR‐ABL fusion protein with abnormal tyrosine kinase activation. Classical tyrosine kinase inhibitor (TKI)‐based therapies are available to patients with CML. However, acquired resistance to TKI has be...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Liling, He, Qingyan, Chen, Xin, Liu, Aochu, Ding, Wa, Zhang, Haichuan, Chen, Xinmei, Zhou, Huan, Meng, Yi, Liu, Bingyuan, Peng, Guanjie, Wang, Chunyan, Liu, Jinbao, Shi, Xianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460481/
https://www.ncbi.nlm.nih.gov/pubmed/36082692
http://dx.doi.org/10.1002/ctm2.1038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460481/
https://www.ncbi.nlm.nih.gov/pubmed/36082692
http://dx.doi.org/10.1002/ctm2.1038

Ejemplares similares